Author

Bruce E. Sands

THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY

Bruce E. Sands  et al.

IMPROVEMENT IN INFLAMMATORY BIOMARKER LEVELS THROUGH WEEK 12 IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS PATIENTS TREATED WITH GUSELKUMAB: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
IMPROVEMENT IN INFLAMMATORY BIOMARKER LEVELS THROUGH WEEK 12 IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS PATIENTS TREATED WITH GUSELKUMAB: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY

Bruce E. Sands  et al.

PHARMACOKINETICS AND IMMUNOGENICITY OF MAINTENANCE THERAPY WITH USTEKINUMAB: 2-YEAR RESULTS FROM THE UNIFI LONG-TERM EXTENSION STUDY
PHARMACOKINETICS AND IMMUNOGENICITY OF MAINTENANCE THERAPY WITH USTEKINUMAB: 2-YEAR RESULTS FROM THE UNIFI LONG-TERM EXTENSION STUDY

Bruce E. Sands  et al.

EFFICACY AND SAFETY OF USTEKINUMAB FOR ULCERATIVE COLITIS THROUGH 4 YEARS: FINAL RESULTS FROM THE UNIFI LONG-TERM EXTENSION
EFFICACY AND SAFETY OF USTEKINUMAB FOR ULCERATIVE COLITIS THROUGH 4 YEARS: FINAL RESULTS FROM THE UNIFI LONG-TERM EXTENSION

Bruce E. Sands  et al.

SERUM PROTEIN PROFILES DIFFER WITH USTEKINUMAB AND ADALIMUMAB TREATMENT IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
SERUM PROTEIN PROFILES DIFFER WITH USTEKINUMAB AND ADALIMUMAB TREATMENT IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Bruce E. Sands  et al.

THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 12 INTERIM ANALYSES FROM THE PHASE 2 GALAXI 1 STUDY
THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 12 INTERIM ANALYSES FROM THE PHASE 2 GALAXI 1 STUDY

Bruce E. Sands  et al.

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Bruce E. Sands  et al.

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Bruce E. Sands  et al.

EFFECTS OF USTEKINUMAB INDUCTION AND MAINTENANCE THERAPY ON DISEASE CLEARANCE IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS
EFFECTS OF USTEKINUMAB INDUCTION AND MAINTENANCE THERAPY ON DISEASE CLEARANCE IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS

Bruce E. Sands  et al.

AGREEMENT BETWEEN LOCALLY AND CENTRALLY REVIEWED MAYO ENDOSCOPIC SUBSCORES IN THE UNIFI STUDY OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS: CORROBORATION WITH FECAL CALPROTECTIN AND HISTOLOGY
AGREEMENT BETWEEN LOCALLY AND CENTRALLY REVIEWED MAYO ENDOSCOPIC SUBSCORES IN THE UNIFI STUDY OF USTEKINUMAB IN PATIENTS WITH ULCERATIVE COLITIS: CORROBORATION WITH FECAL CALPROTECTIN AND HISTOLOGY

Bruce E. Sands  et al.

PATIENT-REPORTED OUTCOMES OF RESPONSE AND REMISSION FOLLOWING GUSELKUMAB INDUCTION TREATMENT AS MEASURED BY THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE: RESULTS THROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY
PATIENT-REPORTED OUTCOMES OF RESPONSE AND REMISSION FOLLOWING GUSELKUMAB INDUCTION TREATMENT AS MEASURED BY THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE: RESULTS THROUGH WEEK 12 OF THE PHASE 2 GALAXI 1 STUDY

Bruce E. Sands  et al.

ORAL ABX464 QD IS EFFICACIOUS AND SAFE DURING PHASE 2B INDUCTION AND MAINTENANCE TREATMENT OF ULCERATIVE COLITIS PATIENTS
ORAL ABX464 QD IS EFFICACIOUS AND SAFE DURING PHASE 2B INDUCTION AND MAINTENANCE TREATMENT OF ULCERATIVE COLITIS PATIENTS

Bruce E. Sands  et al.

EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS IN PATIENTS THROUGH 3 YEARS: UNIFI LONG-TERM EXTENSION
EFFICACY OF USTEKINUMAB FOR ULCERATIVE COLITIS IN PATIENTS THROUGH 3 YEARS: UNIFI LONG-TERM EXTENSION

Bruce E. Sands  et al.

Item 61 - 73 / 73
1 2 3
4